Maze raises $150M at premium; Phase 1 MZE782 data positive, Phase 2 in 2026

Maze Therapeutics, Inc.

Oversubscribed private placement of $150M gross proceeds at $16.25/share (premium to last close), closed Sept 12.
Issued 4M shares and 5.23M pre-funded warrants; investors include Frazier, Deep Track, Janus Henderson, others.
Phase 1 MZE782 in 112 healthy volunteers: 42-fold urinary Phe excretion, no SAEs, well tolerated.
Dose-dependent eGFR dip similar to SGLT2 inhibitors observed; plans for Phase 2 in PKU and CKD in 2026.
Proceeds to advance MZE829 in APOL1 kidney disease, MZE782 Phase 2, Compass platform, and working capital.

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Maze Therapeutics, Inc. issued up to an aggregate of 5,231,090 shares of Common Stock of warrant to certain institutional and accredited investors for $16.249 per Pre-Funded Warrant.

Security: warrant
Shares: up to an aggregate of 5,231,090 shares of Common Stock
Purchaser: certain institutional and accredited investors
Consideration: $16.249 per Pre-Funded Warrant

Exact text from the filing

Placement ”) an aggregate of (i) 4,000,002 shares (the “ Shares ”) of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), at a purchase price of $16.25 per share and (ii) in lieu of shares of Common Stock for certain Investors, pre-funded warrants (the “ Pre-Funded Warrants ”) to purchase up to an aggregate of 5,231,090 shares of

View on SEC.gov

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Maze Therapeutics, Inc. issued 4,000,002 shares of common stock to certain institutional and accredited investors for $16.25 per share.

Security: common stock
Shares: 4,000,002 shares
Purchaser: certain institutional and accredited investors
Consideration: $16.25 per share

Exact text from the filing

Placement ”) an aggregate of (i) 4,000,002 shares (the “ Shares ”) of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), at a purchase price of $16.25 per share and (ii) in lieu of shares of Common Stock for certain Investors, pre-funded warrants (the “ Pre-Funded Warrants ”) to purchase up to an aggregate of 5,231,090 shares of

View on SEC.gov

32 equity issuances filed in the last 30 days. Browse all equity issuances →

Maze Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-200760

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.